SCHEMBL14798339

SCHEMBL14798339

CN(C)CCCCC(C(N)=O)c1cccc(C(C)(O)c2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 2/20 0.43
LMNA P02545 2/20 0.40
HTR2A P28223 2/20 0.40
HRH1 P35367 2/20 0.40
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.36
TTR P02766 1/20 0.36
KMT2A Q03164 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
BCL2 P10415 1/20 0.36
EPHX1 P07099 1/20 0.35
OPRM1 P35372 2/20 0.35
DRD3 P35462 2/20 0.35
DRD2 P14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14798226 0.82 HTR2A (0.44) CCR2LMNAHTR2AHRH1KDM4E
SCHEMBL14798442 0.81 ALDH1A1 (0.44) CCR2LMNAHTR2AHRH1KDM4E
SCHEMBL4903496 0.80 PTGS1 (0.47) CCR2LMNAHTR2AHRH1KDM4E
SCHEMBL4903451 0.79 ALDH1A1 (0.53) CCR2LMNAHTR2AHRH1KDM4E
SCHEMBL4901528 0.79 BCHE (0.41) CCR2LMNAHTR2AHRH1KDM4E
SCHEMBL22322971 0.79 HTR2A (0.59) CCR2LMNAHTR2AHRH1KDM4E
SCHEMBL14797924 0.78 KDM4E (0.43) CCR2LMNAHTR2AHRH1KDM4E
SCHEMBL4909459 0.77 ALDH1A1 (0.40) CCR2LMNAHTR2AHRH1KDM4E
SCHEMBL4903456 0.75 CHRM1 (0.41) CCR2LMNAHTR2AHRH1KDM4E
SCHEMBL12129513 0.68 PTGS1 (0.55) LMNAKDM4EALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493402-B2 Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells DOMPÉ FARMACEUTICI S.P.A. (IT) 2016-11-15 US disclosed
US-20130079514-A1 \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ Dompé S.p.A. (IT) 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079514-A1 \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ C5AR2, C3AR1, C5AR1 CCR2 5/4885LMNA 2539/4885HTR2A 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.